Travere Therapeutics Inc.

NASDAQ: TVTX · Real-Time Price · USD
18.72
0.49 (2.69%)
At close: Aug 15, 2025, 12:49 PM

Travere Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-320.63M -376.33M -278.48M -180.09M
Depreciation & Amortization
43.55M 38.53M 33.08M 26.62M
Stock-Based Compensation
36.91M 44.25M 38.14M 29.57M
Other Working Capital
-35.64M 446K 1.34M 79.08M
Other Non-Cash Items
2.69M 39.01M 19.03M 23.82M
Deferred Income Tax
n/a n/a n/a 4.12M
Change in Working Capital
n/a -25.48M 904K 79.98M
Operating Cash Flow
-237.47M -280.02M -186.29M -14.79M
Capital Expenditures
-101.21M -668K -28.56M -24.15M
Cash Acquisitions
n/a n/a n/a 19.05M
Purchase of Investments
-125.76M -443.94M -385.39M -547.08M
Sales Maturities Of Investments
326.33M 334.57M 381.99M 433.6M
Other Investing Acitivies
-101.25M 165.81M -600K -19.05M
Investing Cash Flow
99.33M 55.78M -32.55M -137.62M
Debt Repayment
n/a n/a 95.04M n/a
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
4.68M 27.55M 2.98M 6.75M
Financial Cash Flow
139.42M 218.75M 117.57M 231.68M
Net Cash Flow
359K -3.51M -104.06M 80.98M
Free Cash Flow
-338.69M -322.28M -214.85M -38.94M